Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BB710 Metabolite 2
- Development stage
- Unknown
- Lead developer
- BalinBac Therapeutics
- Modality
- Small Molecules
- Administration
- Inhalation, Oral
01
Overview
**BB710 Metabolite 2** is a BalinBac Therapeutics investigational COVID-19 program within the BB-700 series. It is described as a combination of repurposed generic drugs intended for oral and inhalation delivery, with proposed multi-mechanistic antiviral activity against SARS-CoV-2 involving viral entry or attachment, spike or protease processes, RNA-dependent RNA polymerase activity, and host metabolic-response pathways. The precise active-ingredient composition and the specific molecular targets of this individual BB710 metabolite program have not been publicly disclosed. BalinBac describes the broader BB-700 series as combinations of two or more generic drugs for COVID-19. ([balinbac.com](https://www.balinbac.com/pipeline))
Beyond the preview
Go deeper on BB710 Metabolite 2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BB710 Metabolite 2.